Scarica l'app Stockscreener
0.1083
2.87%
-0.0032
Dopo l'orario di chiusura:
.11
0.0017
+1.57%
Precedente Chiudi:
$0.1115
Aprire:
$0.1127
Volume 24 ore:
1.38M
Relative Volume:
1.08
Capitalizzazione di mercato:
$6.92M
Reddito:
$1.47M
Utile/perdita netta:
$-97.61M
Rapporto P/E:
-0.0727
EPS:
-1.49
Flusso di cassa netto:
$-80.90M
1 W Prestazione:
+3.14%
1M Prestazione:
-7.12%
6M Prestazione:
-58.17%
1 anno Prestazione:
-97.66%
Intervallo 1D:
$0.1074
$0.115
Intervallo di 1 settimana:
$0.0955
$0.1246
Portata 52W:
$0.082
$4.71
Lyra Therapeutics Inc Stock (LYRA) Company Profile
Nome
Lyra Therapeutics Inc
Settore
Industria
Telefono
617-373-4600
Indirizzo
480 ARSENAL WAY, WATERTOWN, MA
Confronta LYRA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LYRA
Lyra Therapeutics Inc
|
0.1083 | 6.92M | 1.47M | -97.61M | -80.90M | -1.49 |
|
VRTX
Vertex Pharmaceuticals Inc
|
501.15 | 126.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
605.61 | 65.06B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
649.67 | 37.54B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
259.39 | 32.56B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
255.77 | 26.40B | 3.81B | -644.79M | -669.77M | -6.24 |
Lyra Therapeutics Inc Stock (LYRA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-05-07 | Downgrade | BofA Securities | Buy → Underperform |
| 2024-05-07 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2024-05-07 | Downgrade | Jefferies | Buy → Hold |
| 2024-05-06 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2023-10-06 | Ripresa | BTIG Research | Buy |
| 2023-08-31 | Iniziato | H.C. Wainwright | Buy |
| 2022-05-24 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-05-26 | Iniziato | BTIG Research | Buy |
| 2020-05-26 | Iniziato | BofA/Merrill | Buy |
| 2020-05-26 | Iniziato | Jefferies | Buy |
| 2020-05-26 | Iniziato | William Blair | Outperform |
Mostra tutto
Lyra Therapeutics Inc Borsa (LYRA) Ultime notizie
Lyra Therapeutics Inc (LYRA) expanding its growth trajectory ahead - Sete News
Financial Fitness Check: Examining B. Riley Financial Inc (RILY)’s Key Ratios - DWinneX
Rhinitis Pipeline 2025: Groundbreaking Clinical Advancements - openPR.com
Keeping an Eye on Lyra Therapeutics Inc (LYRA) After Insider Trading Activity - knoxdaily.com
Lyra Therapeutics Inc (LYRA) Stock: 52-Week Performance Showcases Highs, Lows, and Trading Volume - investchronicle.com
What was Lyra Therapeutics Inc (LYRA)’s performance in the last session? - uspostnews.com
Recent Insider Activity Could Benefit Schrodinger Inc (SDGR) - knoxdaily.com
Layoff Tracker: Ono Cuts 83 Employees in Massachusetts - BioSpace
Lyra Therapeutics (LYRA) Expected to Announce Quarterly Earnings on Tuesday - American Banking and Market News
iCoreConnect Inc [ICCT] Shares Fall Approximately -87.86% Over the Year - knoxdaily.com
Lyra Therapeutics Inc [LYRA] Shares Rise 7.02 % on Thursday - knoxdaily.com
QBTS Stock Sees Surge of Approximately 14.13% in Last Five Days - knoxdaily.com
Deckers Outdoor Corp [DECK] Records 200-Day SMA of $160.33 - knoxdaily.com
Shopify Inc [SHOP] Records 50-Day SMA of $99.94 - knoxdaily.com
Analysts Say Lyra Therapeutics Inc (NASDAQ:LYRA) Can Really Get To 0.5 In 12 Months - Marketing Sentinel
An Analysis of Lyra Therapeutics Inc (LYRA)’s Potential Price Growth - knoxdaily.com
Take off with Lyra Therapeutics Inc (LYRA): Get ready for trading - Sete News
Is Lyra Therapeutics Inc (LYRA) worth investing in despite its undervalued state? - uspostnews.com
Brokerages Set Lyra Therapeutics, Inc. (NASDAQ:LYRA) Target Price at $1.25 - Defense World
Lyra Therapeutics stock hits 52-week low at $0.1 By Investing.com - Investing.com Australia
Lyra Therapeutics stock hits 52-week low at $0.1 - Investing.com
TCBI Stock Sees Decline of Approximately -2.19% in Last Five Days - knoxdaily.com
Mateon Therapeutics (OTCMKTS:MATN) Share Price Passes Above Two Hundred Day Moving Average – Should You Sell? - Defense World
Vivos Therapeutics, Inc. (VVOS) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance
Lyra Therapeutics stock hits 52-week low at $0.14 amid sharp decline By Investing.com - Investing.com South Africa
Lyra Therapeutics stock hits 52-week low at $0.14 amid sharp decline - Investing.com Australia
PTCT Stock Sees Decline of Approximately -2.93% in Last Five Days - knoxdaily.com
Lyra Therapeutics Inc (LYRA) deserves deeper analysis - uspostnews.com
A Closer Look at Lyra Therapeutics Inc (LYRA) Stock Gains - investchronicle.com
Lyra Therapeutics stock plunges to 52-week low of $0.16 By Investing.com - Investing.com Australia
Lyra Therapeutics stock plunges to 52-week low of $0.16 - Investing.com India
Analysts Set Lyra Therapeutics, Inc. (NASDAQ:LYRA) Target Price at $4.50 - Defense World
Analysts Set TScan Therapeutics, Inc. (NASDAQ:TCRX) PT at $9.33 - Defense World
Lyra Therapeutics (NASDAQ:LYRA) Earns “Neutral” Rating from HC Wainwright - Defense World
Lyra Therapeutics Reports 2024 Financial Results and Updates - TipRanks
Arbor Realty Trust Closes a $1.15 Billion Repurchase Facility to Unwind Two Outstanding Collateralized Loan Obligations - The Manila Times
Lyra Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewswire
FDA Green Light: Lyra's Nasal Polyp Treatment Advances as 52-Week Data Shows Promise - StockTitan
Lyra Therapeutics reports Q4 EPS ($1.43), consensus (13c) - TipRanks
Lyra Therapeutics (LYRA) to Release Quarterly Earnings on Thursday - Defense World
Zevra Therapeutics (ZVRA) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Kailera Therapeutics Launches with $400 Million Series A Financing to Advance Portfolio of Next-Generation Therapies for Obesity and Related Conditions - Bain Capital
Chronic Rhinosinusitis Pipeline 2024: FDA Updates, Therapy - openPR.com
Lyra Therapeutics Inc Azioni (LYRA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.47%
2.63%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):